[Skip to Navigation]
Views 448
Citations 0
Invited Commentary
March 17, 2021

Safety of Neoadjuvant Chemoradiotherapy Followed by Surgery for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Author Affiliations
  • 1Department of Surgery, Escola Paulista de Medicina, São Paulo, Brazil
  • 2Department of Surgery, University of North Carolina, Chapel Hill
JAMA Surg. 2021;156(5):452. doi:10.1001/jamasurg.2021.0134

In a prospective multicenter randomized clinical trial in this issue of JAMA Surgery, Wang and colleagues1 compared the survival and safety of neoadjuvant chemoradiotherapy (nCRT) followed by minimally invasive esophagectomy with that of neoadjuvant chemotherapy (nCT) followed by minimally invasive esophagectomy for patients with locally advanced esophageal squamous cell carcinoma. The primary outcome of this randomized clinical trial is 3-year survival, while postoperative morbidity, mortality, and pathologic response are secondary outcomes.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words